Activating mutations in CTNNB1 gene encoding β-catenin is encountered in approximately 30% of hepatocellular carcinoma (HCC) and in more than 80% of […]
PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant […]
The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore […]
Extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive haematological malignancy. The treatment of ENKTCL is dependent on the extent of […]
EVs are being recognized as vectors for drug delivery. In particular, EV loading with targeting and therapeutic agents brings along an interesting […]
The inventors have developed a new system of optogenetics-based recombinant system allowing to target tumor cells to control in space and time tumor […]
The present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment […]
Tumour-specific molecular targets and alternative therapeutic strategies for triplenegative breast cancer (TNBC) are urgently needed. The protease […]
The present invention relates to the treatment of cancer and particularly of lung cancer. In the present study, the inventors analyzed the role of the […]
The present invention relates to a method for preventing or treating a cancer disease by targeting the epigenetic factor Chromodomain on Y-like 2 […]